FB Pixel no scriptHengrui inks licensing deal with GSK
MENU
KrASIA
Jul
28

Hengrui inks licensing deal with GSK

just now
Hengrui Pharmaceuticals has licensed global rights to its HRS-9821 program and granted GSK options on up to 11 additional candidates, excluding Greater China. GSK will pay USD 500 million upfront, with milestone payments tied to development, registration, and sales potentially totaling up to USD 12 billion.
Share

Latest Pulses

See All

Most Recent